A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Aug 12

PMID 35954464

Authors

Dmitry Enikeev

Andrey Morozov

Diana Babaevskaya

Andrey Bazarkin

Bernard Malavaud

Affiliations

Soon will be listed here.

Abstract

The purpose of the review is to summarize the recent data on circulating tumor cells (CTC) use in clinical practice. We performed a systematic literature search using two databases (Medline and Scopus) over the past five years and the following terms: (CTC OR "circulating tumor cells" OR "liquid biopsy") AND prostate. The primary outcome was CTC predictive value for prostate cancer (PC) progression and survival. The secondary outcomes were the CTC predictive value for therapy response and the results of CTC detection depending on the assessment method. In metastatic PC, the CTC count showed itself to be a prognostic marker in terms of clinically important features, namely survival rates and response to treatment. CTC concentration was significantly associated with the overall survival and progression-free survival rates. A strong association between the overall survival or progression-free survival rate and CTC concentration could be observed. Variant-7 androgen receptors-positive (AR-V7-positive) patients showed a poor response to androgen receptor signaling (ARS) inhibitors, but this did not compromise their response to taxanes. In localized PC, only positive Cluster of Differentiantion 82 protein (CD82+) correlated with a higher survival rate. CTC count and AR-V7 expression showed itself to be a valuable biomarker for survival in metastatic PC and response to ARS-inhibitors. CTC diagnostic performance for localized PC or for screening and early detection is not high enough to show additional value over the other biomarkers.

Citing Articles

Minimally invasive cytoreductive radical prostatectomy, exploring the safety and feasibility of a single-port or multi-port robotic platform.

Lama D, Thomas K, Vernez S, Okunowo O, Lau C, Yuh B BMC Urol. 2024; 24(1):72.

PMID: 38532371 PMC: 10964602. DOI: 10.1186/s12894-024-01463-2.

Beyond Prostate Cancer: An Androgen Receptor Splice Variant Expression in Multiple Malignancies, Non-Cancer Pathologies, and Development.

Katleba K, Ghosh P, Mudryj M Biomedicines. 2023; 11(8).

PMID: 37626712 PMC: 10452427. DOI: 10.3390/biomedicines11082215.

Protocol for a prospective study evaluating circulating tumour cells status to predict radical prostatectomy treatment failure in localised prostate cancer patients (C-ProMeta-1).

Al-Hammouri T, Almeida-Magana R, Lawrence R, Duffy T, White L, Burke E BMC Cancer. 2023; 23(1):581.

PMID: 37353740 PMC: 10288675. DOI: 10.1186/s12885-023-11081-0.

Biomarkers of Aggressive Prostate Cancer at Diagnosis.

Boehm B, York M, Petrovics G, Kohaar I, Chesnut G Int J Mol Sci. 2023; 24(3).

PMID: 36768533 PMC: 9916581. DOI: 10.3390/ijms24032185.

References

Pereira-Veiga T, Gonzalez-Conde M, Leon-Mateos L, Pineiro-Cid R, Abuin C, Muinelo-Romay L . Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers. Clin Exp Metastasis. 2021; 38(2):239-251. PMC: 7987626. DOI: 10.1007/s10585-021-10075-1. View

Massard C, Oulhen M, Moulec S, Auger N, Foulon S, Abou-Lovergne A . Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study. Oncotarget. 2016; 7(34):55069-55082. PMC: 5342402. DOI: 10.18632/oncotarget.10396. View

Puche-Sanz I, Alvarez-Cubero M, Pascual-Geler M, Rodriguez-Martinez A, Delgado-Rodriguez M, Garcia-Puche J . A comprehensive study of circulating tumour cells at the moment of prostate cancer diagnosis: biological and clinical implications of EGFR, AR and SNPs. Oncotarget. 2017; 8(41):70472-70480. PMC: 5642570. DOI: 10.18632/oncotarget.19718. View

Meyer C, Pantel K, Tennstedt P, Stroelin P, Schlomm T, Heinzer H . Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. Urol Oncol. 2016; 34(5):235.e11-6. DOI: 10.1016/j.urolonc.2015.12.003. View

Vogelzang N, Fizazi K, Burke J, de Wit R, Bellmunt J, Hutson T . Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016; 71(2):168-171. DOI: 10.1016/j.eururo.2016.07.051. View

Hara N, Kasahara T, Kawasaki T, Bilim V, Tomita Y, Obara K . Frequency of PSA-mRNA-bearing cells in the peripheral blood of patients after prostate biopsy. Br J Cancer. 2001; 85(4):557-62. PMC: 2364088. DOI: 10.1054/bjoc.2001.1924. View

Nagaya N, Nagata M, Lu Y, Kanayama M, Hou Q, Hotta Z . Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. PLoS One. 2020; 15(1):e0226219. PMC: 6984691. DOI: 10.1371/journal.pone.0226219. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Murray N, Aedo S, Fuentealba C, Reyes E . 10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy. Asian Pac J Cancer Prev. 2018; 19(6):1577-1583. PMC: 6103576. DOI: 10.22034/APJCP.2018.19.6.1577. View

10.

Sepe P, Verzoni E, Miodini P, Claps M, Ratta R, Martinetti A . Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. Cancers (Basel). 2019; 11(7). PMC: 6678845. DOI: 10.3390/cancers11070980. View

11.

Zhu M, Kyprianou N . Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 2009; 24(3):769-77. PMC: 2830130. DOI: 10.1096/fj.09-136994. View

12.

Choi S, Lim B, Kyung Y, Kim Y, Kim B, Jeon B . Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance. In Vivo. 2019; 33(5):1615-1620. PMC: 6755012. DOI: 10.21873/invivo.11645. View

13.

Tsumura H, Satoh T, Ishiyama H, Tabata K, Takenaka K, Sekiguchi A . Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer. Int J Mol Sci. 2017; 18(1). PMC: 5297762. DOI: 10.3390/ijms18010128. View

14.

Zapatero A, Gomez-Caamano A, Cabeza Rodriguez M, Muinelo-Romay L, de Vidales C, Abalo A . Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study. Radiat Oncol. 2020; 15(1):137. PMC: 7268302. DOI: 10.1186/s13014-020-01577-5. View

15.

Okegawa T, Itaya N, Hara H, Tambo M, Nutahara K . Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy. Int J Mol Sci. 2016; 17(12). PMC: 5187808. DOI: 10.3390/ijms17122008. View

16.

Graf R, Hullings M, Barnett E, Carbone E, Dittamore R, Scher H . Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer. Eur Urol. 2019; 77(2):170-177. PMC: 7472426. DOI: 10.1016/j.eururo.2019.08.020. View

17.

Knipper S, Riethdorf S, Werner S, Tilki D, Graefen M, Pantel K . Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence. Eur Urol Open Sci. 2021; 34:55-58. PMC: 8579141. DOI: 10.1016/j.euros.2021.09.017. View

18.

Hofmann L, Sallinger K, Haudum C, Smolle M, Heitzer E, Moser T . A Multi-Analyte Approach for Improved Sensitivity of Liquid Biopsies in Prostate Cancer. Cancers (Basel). 2020; 12(8). PMC: 7465186. DOI: 10.3390/cancers12082247. View

19.

Theil G, Fischer K, Weber E, Medek R, Hoda R, Lucke K . The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study. PLoS One. 2016; 11(8):e0158354. PMC: 4968821. DOI: 10.1371/journal.pone.0158354. View

20.

Ladurner M, Wieser M, Eigentler A, Seewald M, Dobler G, Neuwirt H . Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer. Biomedicines. 2021; 9(8). PMC: 8391593. DOI: 10.3390/biomedicines9081004. View